Contents

Chapter 1

Primary and Postprimary Tuberculosis **1**

◊ Primary Tuberculosis *1*
◊ Postprimary Tuberculosis *5*

Chapter 2

Case Definitions in Tuberculosis **11**

◊ Case Definitions *11*
◊ Disease Classification *12*
◊ Types of Tuberculosis Patients *14*
◊ HIV Setting Case Definitions *18*

Chapter 3

Epidemiology of Tuberculosis **21**

◊ Epidemiological Indices *21*
◊ Epidemiological Survey Methods *23*
◊ Survey Method in TB *23*
◊ Global Burden of TB *24*
◊ TB Burden in India *25*
◊ WHO Estimate of TB Burden *27*

Chapter 4

Diagnostic Tools for Tuberculosis **31**

◊ Diagnosis of Latent TB Infection *31*
◊ Interferon-(γ) Assays *35*
◊ Diagnosis of Tuberculosis *37*
◊ Other Investigations in the Diagnosis of Tuberculosis *49*

Chapter 5

Basic Concepts in Treatment of Tuberculosis **51**

◊ Role of Special Diet and Rest *51*
◊ Role of Hospitalization *51*
◊ Single Drug Therapy vs Multiple Drugs *52*
◊ Single vs Divided Doses *52*
◊ Optimum Duration of Treatment *52*

◊ Daily vs Intermittent Therapy *53*
◊ Monitoring of Progress of Chemotherapy *53*
◊ Causes of Failure of Chemotherapy *54*
◊ Role of Surgery in Pulmonary Tuberculosis *55*

Chapter 6

How does Tuberculosis Treatment Work? 56
◊ Bacteriological Factors *56*
◊ Environmental Factors *57*
◊ Pharmacological Factors *58*

Chapter 7

Duration of Treatment 60

Chapter 8

Antitubercular Drug Doses and Regimens for Adults and Children 63

Chapter 9

Pharmacology of Antitubercular Drugs Used in new Patients of Tuberculosis 69
◊ Isoniazid *69*
◊ Rifampicin *71*
◊ Ethambutol *72*
◊ Pyrazinamide *73*
◊ Streptomycin *74*

Chapter 10

Pharmacology of Antitubercular Drugs Used in Previously Treated Patients of Tuberculosis 77
◊ Kanamycin *77*
◊ Amikacin *80*
◊ Capreomycin *83*
◊ Cycloserine *85*
◊ Ethionamide and Prothionamide *87*
◊ Para-aminosalicylic Acid (PAS) *90*
◊ Levofloxacin *92*
◊ Moxifloxacin *95*
◊ Ofloxacin *98*
◊ Clofazimine *100*
◊ Thiacetazone *102*
◊ Linezolid *103*
◊ Clarithromycin *104*
◊ Imipenem/Cilastatin *105*

Chapter 11

Adverse Effects of Antitubercular Drugs Used in new Patients of Tuberculosis 109

Chapter 12

Adverse Effects of Antitubercular Drugs Used in Previously Treated Patients of TB **112**

Chapter 13

Treatment of Tuberculosis in Special Conditions: Pregnancy, Liver Disease and Renal Disease **121**

◊ Treatment of Tb in Pregnancy and Lactation *121*
◊ Treatment of TB in Renal Insufficiency *122*
◊ Treatment of Tb in Liver Diseases *125*

Chapter 14

Case-based Approach for Treatment of Tuberculosis in Special Conditions **128**

◊ Treatment of TB in pregnancy and lactation *128*
◊ Treatment of TB in renal insufficiency *129*
◊ Treatment of TB in liver disease *130*

Chapter 15

Current Concepts in the Treatment of Extrapulmonary Tuberculosis **132**

◊ Tuberculous Lymphadenitis *133*
◊ Pleural Effusion *133*
◊ Tuberculous Meningitis (TBM) *134*
◊ Bone and Joint Tuberculosis *134*
◊ Miliary Tuberculosis *135*
◊ Tuberculous Pericarditis *135*
◊ Abdominal Tuberculosis *135*
◊ Genitourinary Tuberculosis *136*
◊ Ocular Tuberculosis *136*
◊ Upper Respiratory Tract Tuberculosis *136*
◊ Cutaneous Tuberculosis *136*

Chapter 16

Use of Corticosteroids in Tuberculosis **138**

◊ Indications of Corticosteroids in Tuberculosis *138*
◊ Dose and Duration of Corticosteroids *141*

Chapter 17

Management Strategies of Retreatment Cases in Tuberculosis **142**

◊ Relapse *142*
◊ Defaulters or Treatment After Default *142*
◊ Failure *143*
◊ Poor Adherence to Treatment *143*
◊ Drug Resistance in Tuberculosis *143*
◊ Approach to Retreatment Cases *143*
◊ Non-MDR *144*

◊ Chronic TB case *144*
◊ MDR-TB *144*
◊ Prevention of Retreatment Cases *145*

Chapter 18

Multidrug Resistant Tuberculosis (MDR-TB): Current Scenario **147**
◊ Types of Drug Resistance *147*
◊ Prevalence of MDR-TB: Global *147*
◊ Prevalence of MDR-TB in India *151*
◊ HIV Infection and Multidrug-resistant TB *154*
◊ Risk Factors of MDR-TB *155*
◊ Control of MDR-TB *156*

Chapter 19

Drug Resistant and Multidrug Resistant Tuberculosis: Management **159**
◊ Definition *159*
◊ Impact of Drug Resistance on the Outcome of Chemotherapy *159*
◊ Diagnosis of Drug Resistant and Multidrug Resistant Tuberculosis *160*
◊ Treatment of Drug Resistant and Multidrug Resistant Tuberculosis *163*
◊ DOTS-PLUS *167*
◊ Outcome of Treatment *170*

Chapter 20

Multidrug Resistant Tuberculosis Management: Case-based Approach **172**
◊ Case I *172*
◊ CASE II *172*
◊ CASE III *174*
◊ CASE IV *177*
◊ CASE V *177*
◊ CASE VI *180*

Chapter 21

Monitoring During Treatment of MDR & XDR-TB **182**

Chapter 22

Extensively Drug Resistant Tuberculosis (XDR-TB) **184**
◊ Epidemiology *184*
◊ Factors Responsible for XDR-TB *186*
◊ Diagnosis *186*
◊ Treatment *187*
◊ Monitoring of Treatment *189*
◊ Role of Surgery *190*
◊ HIV and XDR-TB *190*
◊ Xdr-TB in Pediatric Patients *190*
◊ XDR-TB in Pregnancy *191*
◊ Control of XDR-TB *192*

Chapter 23

Complications of Tuberculosis **194**
◊ Hemoptysis *194*
◊ Fungus Ball *195*
◊ Bronchiectasis *197*
◊ Tuberculosis Endobronchitis and Tracheitis *197*
◊ Spontaneous Pneumothorax *198*
◊ Calcification *198*
◊ Tuberculous Laryngitis *198*
◊ Tuberculosis Enteritis *198*
◊ Open Negative Syndrome *199*
◊ Scar Carcinoma *199*
◊ Physiological Changes *200*
◊ Amyloidosis *201*
◊ Chronic Respiratory Failure *201*
◊ Chronic Cor Pulmonale *202*

Chapter 24

Bacillus Calmette Guérin (BCG) **205**
◊ Basis of Giving BCG *205*
◊ Types of BCG Vaccine *205*
◊ Dose and Site of Vaccination *206*
◊ Routes of Vaccination *206*
◊ Efficacy and Safety *206*
◊ Contraindications to BCG Vaccination *207*
◊ Normal Reaction after BCG Vaccination *207*
◊ Complications *207*
◊ Newer Vaccines *210*

Chapter 25

Chemoprophylaxis **215**
◊ Chemoprophylaxis in tuberculosis *215*

Chapter 26

The Revised National Tuberculosis Control Program **219**
◊ RNTCP Strategy *219*
◊ RNTCP Structure *220*
◊ Diagnosis under RNTCP *221*
◊ Diagnosis of Childhood Tuberculosis *222*
◊ Treatment Regimen Used in RNTCP *226*
◊ Achievements of RNTCP *228*
◊ Other Priority Initiatives in RNTCP *230*
◊ DOTS-plus *234*

Chapter 27

Tuberculosis and HIV **241**

◊ Epidemiology *241*
◊ Impact of HIV on TB *242*
◊ Impact of Tuberculosis on HIV *242*
◊ Diagnostic Difficulties in Persons with HIV/ Tuberculosis Coinfection *242*
◊ Revised WHO Clinical Staging Of HIV/AIDS for Adults *243*
◊ And Adolescents with Confirmed HIV Infection *243*
◊ Diagnosis of Pulmonary Tuberculosis *244*
◊ Diagnosis of Extrapulmonary Tuberculosis *245*
◊ Investigations *247*
◊ Treatment of Tuberculosis in HIV Positive Patients *248*

Chapter 28

Interaction Between Antitubercular and Antiretroviral Drugs **256**

◊ Antiretroviral Therapy for the Treatment of HIV Infection 256

Chapter 29

Overlying and Additive Toxicities of Antiretroviral Therapy (ART) and Antituberculosis Therapy **263**

Chapter 30

Tuberculosis in Children **268**

◊ Epidemiology *268*
◊ Clinical Presentation of Tuberculosis *269*
◊ Diagnosis of Childhood Tuberculosis *269*
◊ Treatment of Tuberculosis in Children *273*

Chapter 31

Non-tubercular Mycobacteria **277**

◊ Epidemiology *277*
◊ Mode of Infections *278*
◊ Classifications of NTM *278*
◊ Distribution *279*
◊ Clinical Presentations 280
◊ Diagnosis 280
◊ Treatment 284

Chapter 32

Hemoptysis **288**

◊ Pseudo or Spurious Hemoptysis *288*
◊ Grades of Hemoptysis *289*
◊ Recurrent Hemoptysis *289*

◊ Etiology of Hemoptysis *289*
◊ Hemoptysis with Normal Chest X-Ray *291*
◊ Mechanism of Bleeding *291*
◊ Pathogenesis of Hemoptysis in Tuberculosis *291*
◊ Diagnosis of Hemoptysis *292*
◊ Treatment of Hemoptysis *294*

Chapter 33

Miliary Tuberculosis **297**
◊ Pathogenesis *297*
◊ Pathology *298*
◊ Diagnosis *299*
◊ Treatment *299*
◊ Complications *300*

Chapter 34

Tuberculosis and Diabetes **302**
◊ Epidemiology *302*
◊ Effect of Diabetes on Pulmonary Tuberculosis *303*
◊ Effect of Pulmonary Tuberculosis on Diabetes *304*
◊ Clinical Features and Course of Tuberculosis in Diabetics *304*
◊ Roentgenographic Aspects of Tuberculosis in Diabetics *305*
◊ MDR-TB and Diabetes *306*
◊ Effect of Antituberculosis Drugs on Blood Glucose Level and OHA in Tubercular Diabetics *306*
◊ Principles of Management *306*

Chapter 35

Tubercular Lymphadenitis **309**
◊ Epidemiology *309*
◊ Pathogenesis *310*
◊ Clinical Features *310*
◊ Diagnosis *312*
◊ Treatment *313*

Chapter 36

Tubercular Empyema **316**
◊ Etiopathogenesis *316*
◊ Clinical Features *317*
◊ Diagnosis *317*
◊ Treatment *318*

Index *323*